Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 12, 2024 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Doses First Patient in Phase 2 Avail™ Trial of MBX 2109 for the Treatment of Hypoparathyroidism

CARMEL, Ind., Aug. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for...
August 05, 2024 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Raises $63.5 Million in Series C Financing to Advance Precision Endocrine Peptide™ (PEP™) Platform

Financing led by Deep Track Capital, with new investments from Driehaus Capital Management and funds and accounts advised by T. Rowe Price Associates, Inc. Proceeds to support ongoing Phase 2...
June 25, 2024 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Appoints Salomon Azoulay, M.D., as Chief Medical Officer

CARMEL, Ind., June 25, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for...
February 05, 2024 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Appoints Steven Ryder, M.D., to Board of Directors

CARMEL, Ind., Feb. 05, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical-stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
January 31, 2024 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
December 20, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Participate in 42nd Annual J.P. Morgan Healthcare Conference

CARMEL, Ind., Dec. 20, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
November 15, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Participate in Piper Sandler 35th Annual Healthcare Conference

CARMEL, Ind., Nov. 15, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
November 01, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Announces Appointment of Michelle Graham as Chief Human Resources Officer

CARMEL, Ind., Nov. 01, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
October 31, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Participate in Stifel 2023 Healthcare Conference

CARMEL, Ind., Oct. 31, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
October 16, 2023 16:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting

MBX 2109 was generally well-tolerated across all dosing cohorts MBX 2109 pharmacokinetics reflected the intended prodrug design and support once-weekly dosing MBX 2109 increased albumin adjusted...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right